Antibodies or receptor tyrosine kinase (RTKs) inhibitors that target VEGF, VEGFR, FGFR, EGFR, or other neoangiogenesis-related molecules represent a significant area of the researches in anti-cancer targeted therapies. This evidence concerns the gene KDR and cancer.